Relmada Therapeutics, Inc. (RLMD) is followed by a small group of analysts, and their individual, attributable targets vary widely. This analysis reviews six verified targets: Mizuho at $19 (raised from $10 in March 2026), Lucid Capital at $14 (initiated March 2026), H.C. Wainwright at $12 (initiated June 2026), Piper Sandler at $12 (initiated March 2026, Overweight), Jefferies at $9 (December 2025), and Leerink Partners at roughly $8 (January 2026).
The arithmetic mean of these six figures is about $12.30, rounded to a central target of $12. The range of roughly $8 to $19 is exceptionally wide — more than double from bottom to top — which reflects genuine disagreement about the value of a pre-commercial pipeline. Aggregators that use narrower coverage windows report slightly different averages (roughly $10.75 to $14.33), so no single figure should be treated as an official consensus. Ratings skew strongly toward Buy, but Weiss Ratings has published a Sell view, underscoring that the stock is not universally regarded as undervalued.
RLMD has recently traded around $4.20, within a 52-week range of roughly $2.97 to $8.00. Reaching the $12 central target would require a gain of about 185% from that level — a very large move, especially given that the shares have never traded at or above $12 in recent history and the prior 52-week high is only $8.
The company is pre-revenue and essentially a binary, event-driven biotech. Its lead candidate, NDV-01, is a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, with an IND filing expected by year-end 2026 and a planned Phase 3 "RESCUE" registrational program. A second candidate, sepranolone, is a neurosteroid being advanced toward a Phase 2 proof-of-concept study for neuropsychiatric conditions. Any sustained re-rating would most plausibly follow positive clinical data, regulatory progress, or a strategic transaction, rather than gradual operational execution.
The bull case rests on a repositioned pipeline and a strong balance sheet. Relmada reported roughly $217.7 million in cash as of June 30, 2026, which management expects to fund operations into 2029 — reducing near-term dilution risk and giving the company room to advance both programs. Analyst targets well above the current price reflect the view that the oncology opportunity, particularly NDV-01 for bladder cancer, is not yet reflected in a market capitalization of roughly $416–455 million.
Upcoming catalysts — the two IND filings and the initiation of registrational and proof-of-concept studies — could serve as positive milestones. In addition, the stock's low beta (about 0.57) and a base of predominantly Buy-rated coverage provide a foundation, though they do not guarantee appreciation.
The central risk is that neither candidate reaches the market. As a pre-revenue company with roughly 17 employees and no approved products, Relmada's valuation is tied almost entirely to future clinical and regulatory success. A failed trial, a delayed IND, or a manufacturing setback could compress the stock toward or below its 52-week low.
The target range itself is a warning: analysts cannot agree on whether the company is worth $8 or $19. Further risks include future equity raises despite the long runway, competitive therapies in bladder cancer and CNS (central nervous system) disorders, and the historical lesson that Relmada's previous lead depression program did not meet its Phase 3 endpoints — a reminder of how quickly clinical-stage value can evaporate.
The shares sit roughly midway between a 52-week low near $2.97 and a 52-week high of $8.00. The $8 level marks the most durable overhead resistance and would need to be cleared decisively before a move toward double digits became plausible. On the downside, the $3 area represents a key support zone, with the psychological $5 level in between. Because the $12 target lies 50% above the prior high, the technical structure alone does not currently support the target; reaching it would require a fundamental catalyst powerful enough to break the long-term range.
Most analyst price targets reflect a research horizon of roughly 12 months, though horizons differ across firms and are not explicitly stated for every target. For a pre-revenue biotech, this effectively means "through the next major data or regulatory milestone" rather than a precise date.
Investors should watch the year-end 2026 IND filings for NDV-01 and sepranolone, the clearance and start of the Phase 3 RESCUE program, quarterly cash updates and any financing activity, and analyst revisions following news. Any of these events could meaningfully shift the target range in either direction.
For traders who prefer a systematic approach to a volatile name like RLMD, Tickeron's AI Daily Buy/Sell Signals offer a data-driven complement to fundamental research. The tool uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover new opportunities, monitor existing positions, and spot shifting trends more efficiently than manual review allows. Exploring the signals can help place analyst targets in a real-time, price-action context.
The $12 central target is the arithmetic mean of six analyst price targets spanning roughly $8 to $19, and it sits about 185% above the recent price near $4.20. Reaching it would require a very large move driven by successful execution of a repositioned, pre-revenue pipeline. The strongest supports are a lengthy cash runway and upcoming regulatory catalysts, while the principal obstacles are binary clinical risk, no revenue, and a target range so wide it underscores genuine uncertainty. Given the spread between the highest and lowest targets and the absence of an approved product, investors should treat $12 as an illustrative scenario tied to future milestones — not a forecast — and monitor the IND filings, the start of the registrational program, and analyst revisions as the next meaningful signposts.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, RLMD has been loosely correlated with XENE. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if RLMD jumps, then XENE could also see price increases.
| Ticker / NAME | Correlation To RLMD | 1D Price Change % | ||
|---|---|---|---|---|
| RLMD | 100% | +1.20% | ||
| XENE - RLMD | 55% Loosely correlated | -1.26% | ||
| NERV - RLMD | 45% Loosely correlated | -3.36% | ||
| DYN - RLMD | 44% Loosely correlated | +0.88% | ||
| DNTH - RLMD | 44% Loosely correlated | -0.72% | ||
| SLDB - RLMD | 42% Loosely correlated | -2.29% | ||
More | ||||